Treatment of MS patients with IFN-β1a 44 μg three times weekly was associated with fewer MR active lesions (P < 0.001 at 24 and 48 weeks) compared to those who were treated with IFN-β1a 30 μg once weekly. The gene discussed is IFNA1; the disease is myeloid sarcoma.